ICD-10 Specific code D46: Myelodysplastic syndromes

Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.

Translations

Language Translation
Flag for English language  English Myelodysplastic syndromes
Flag for French language  French Syndromes myélodysplasiques

Hierarchical position

Level Code Title
1 II Neoplasms
2 D37-D48 Neoplasms of uncertain or unknown behaviour
3 D46 Myelodysplastic syndromes

Contents

Code Title
D46.0 Refractory anaemia without sideroblasts, so stated
D46.1 Refractory anaemia with sideroblasts
D46.2 Refractory anaemia with excess of blasts
D46.3 Refractory anaemia with excess of blasts with transformation
D46.4 Refractory anaemia, unspecified
D46.5 Refractory anaemia with multi-lineage dysplasia
D46.6 Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.7 Other myelodysplastic syndromes
D46.9 Myelodysplastic syndrome, unspecified

Indicated medicines

Active Ingredient

Ifosfamide is an antineoplastic, a cytotoxic alkylating agent. It is a prodrug and shows no in vitro cytotoxic activity until activated by microsomal enzymes. The cytotoxic activity of ifosfamide (alkylation of the nucleophilic centres in the cells) is associated with the activated oxazaphosphorine ring hydroxylated at the C4 atom which interacts with DNA-DNA cross linking. This activity manifests itself by blocking the late S and early G2 phases of the cell cycle.

Melphalan is a bifunctional alkylating agent. Formation of carbonium intermediates from each of the two bis-2-chloroethyl groups enables alkylation through covalent binding with the 7-nitrogen of guanine on DNA, cross-linking the two DNA strands and thereby preventing cell replication.

Selpercatinib is an inhibitor of the rearranged during transfection (RET) receptor tyrosine kinase. Selpercatinib inhibited wild-type RET and multiple mutated RET isoforms as well as VEGFR1 and VEGFR3 with IC50 values ranging from 0.92 nM to 67.8 nM. In in vitro and in vivo tumor models, selpercatinib demonstrated anti-tumor activity in cells harboring constitutive activation of RET protein resulting from gene fusions and mutations, including CCDC6-RET, KIF5B-RET, RET V804M, and RET M918T.

⇈